Potential Regulatory and Commercial Environment for Biosimilars in Latin America

Value in Health Regional Issues

Volumn 1, Issue 2, 2012, Pages 228-234

  Azevedo, Valderilio Feijó ^a,b   Sandorff, Erik ^c   Siemak, Brian ^c   Halbert, Ronald J ^c,d  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Edumed Health and Educational Research   (Brazil)

^c ICON PLC   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biosimilar pharmaceuticals; Drug industry; Drug legislation; Latin America

Indexed keywords

BIOSIMILAR AGENT; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; PEGINTERFERON;

ARGENTINA; ARTICLE; BRAZIL; CHILE; COMPARATIVE STUDY; DRUG COST; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; HEALTH CARE ACCESS; HEALTH SERVICE; HUMAN; LAW; MEXICO; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; VENEZUELA;

EID: 84870921310     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2012.09.015     Document Type: Article

References (10)

1. Castanheira L.G., Barbano D.B., Rech N. Current development in regulation of similar biotherapeutic products in Brazil. Biologicals 2011, 39:308-311.
2. Kirchlechner T. Current regulations of biosimilars in the Latin American region. Paper presented at: 3rd Annual Drug Information Association (DIA) Latin American Regulatory Conference, Panama City, Panama, April 12-15, 2011.
3. Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs) 2009, World Health Organization, WHO Press, Geneva.
4. Pinto V. Biologics and biosimilars in Brazil: regulatory outlook and pharmacoeconomic challenges. In: ISPOR 3rd Latin America Conference. Mexico City, Mexico, September 10, 2011.
5. Federal Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product - Draft Guidance. Rockville, MD: U.S. Department of Health and Human Services, February 2012.
6. Milenio. Medicamento biotecnológico del ISSSTE desata pleito legal. Available from: [Accessed June 14, 2012]. http://jalisco.milenio.com/cdb/doc/impreso/9043982.
7. Milenio. Firma Calderón regulación para medicamentos biotecnológicos. Available from: [Accessed June 6, 2012]. http://www.milenio.com/cdb/doc/noticias2011/a651c69e0f2e1c7955fbbca5a8ff2d9d.
8. Institio de Salud Publica. Gobierno anuncia mesa de trabajo para regular medicamentos biotecnológicos. Available from: [Accessed June 7, 2012]. http://www.ispch.cl/noticia/14038/gobierno-anuncia-mesa-de-trabajo-para-regular-medicamentos-biotecnologicos.
9. Cooperativa. Polémica por insulina india tiene origen comercial, según director de Asilfa. Available from: [Accessed June 8, 2012]. http://www.cooperativa.cl/prontus_nots/site/artic/20060202/pags/20060202190746.html.
10. Argentina Investiga. La Universidad desarrollará medicamentos contra el cáncer. Available from: [Accessed June 11, 2012]. http://argentinainvestiga.edu.ar/english/noticia.php?titulo=the_university_will_develop_medicines_to_treat_cancer&id=1269.